 |
|
|
| |
Extension of Bulevirtide Monotherapy to 72 Weeks in HDV Patients with Compensated Cirrhosis: Efficacy and Safety From the Italian Multicenter Study (HEP4Di)
Interim Analysis
|
| |
| |
AASLD 2022 Nov 4-8
<
MP. Anolli1, E. Degasperi1, G. D'Offizi2, MR. Brunetto3, G. Verucchi4, A. Federico5, A. Ciancio6, A. Mangia7, TA. Santantonio8, N. Coppola9, A. Pellicelli10, A. Loglio11, M. Vigaṇ12, F. Pileri13, M. Maracci14, M. Puoti15, F. Piscaglia16 and P. Lampertico1,17
|
| |
|
|
|
|
|
